Item 2.01. Completion of Acquisition or Disposition of Assets
As described in the Introductory Note above, on
The aggregate consideration paid by Purchaser in the Offer and Merger was
approximately
The information contained in the Introductory Note of this Current Report on Form 8-K is incorporated by reference into this Item 2.01.
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing
In connection with the consummation of the Merger, the Company (i) notified the
Nasdaq Global Select Market ("NASDAQ") of the consummation of the Merger and
(ii) requested that NASDAQ (A) suspend trading of the Shares effective before
the opening of trading on
Item 3.03. Material Modification to Rights of Security Holders
The information contained in the Introductory Note and Items 2.01, 3.01 and 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03.
Item 5.01. Changes in Control of Registrant
The information contained in the Introductory Note and Items 2.01, 5.02 and 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 5.01.
Item 5.02. Departure of Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers
Pursuant to the terms of the Merger Agreement, at the effective time of the
Merger, the directors and officers of Purchaser as of immediately prior to the
effective time of the Merger became the directors and officers of the
Information about
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, the Company's amended and restated certificate of incorporation and the Company's amended and restated bylaws were amended and restated in their entirety, as set forth in Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K, and are incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits. Exhibit Description 2.1 Agreement and Plan of Merger, dated as ofMay 5, 2020 , by and amongPortola Pharmaceuticals, Inc. , Alexion Pharmaceuticals, Inc. andOdyssey Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by the Company with theSEC onMay 7, 2020 ). 3.1 Amended and Restated Certificate of Incorporation of the Company. 3.2 Amended and Restated Bylaws of the Company. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
© Edgar Online, source